A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

[1]  Vitor Mendes Pereira,et al.  In Reply. , 2011, Neurosurgery.

[2]  S. Steinberg,et al.  Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. , 2008, The Journal of urology.

[3]  C. Tangen,et al.  Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916 , 2008 .

[4]  B. Trock,et al.  The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. , 2008, The Journal of urology.

[5]  N. Mottet,et al.  The role of intermittent androgen deprivation in prostate cancer , 2007, BJU international.

[6]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[8]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Steinberg,et al.  A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. , 2005, The Journal of urology.

[10]  B. Eser,et al.  Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[12]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Walsh,et al.  A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. , 2001, The Journal of urology.

[14]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[15]  A W Partin,et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.

[16]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  W. Figg,et al.  Pharmacokinetics of thalidomide in an elderly prostate cancer population. , 1999, Journal of pharmaceutical sciences.

[18]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[19]  B. Chauvet,et al.  [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[20]  R. A. Jones,et al.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997, British journal of urology.

[21]  A. Zietman,et al.  The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. , 1995, International journal of radiation oncology, biology, physics.

[22]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[23]  H. Sasaki,et al.  Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study , 1992, The Journal of pathology.